NUVBNuvation BioNUVB info
$2.67info-0.74%24h
Global rank10797
Market cap$581.91M
Change 7d1.91%
YTD Performance78.00%
SP500 benchmarkOutperform
P/E0
P/S0
Revenue$0
Earnings$0
Dividend yield-
Main Sector
Healthcare
Business data

    Nuvation Bio (NUVB) Stock Overview

    Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to anti-cancer warheads of existing drugs, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. Nuvation Bio Inc. was founded in 2018 and is headquartered in New York, New York.

    NUVB Stock Information

    Symbol
    NUVB
    Address
    1500 BroadwayNew York, NY 10036United States
    Founded
    -
    Trading hours
    9:30 AM - 4:00 PM ET
    Website
    https://www.nuvationbio.com
    Country
    πŸ‡ΊπŸ‡Έ United States
    Phone Number
    332 208 6102

    Nuvation Bio (NUVB) Price Chart

    -
    Value:-

    Nuvation Bio Overview: Key Details and Summary

    Stock data
    2024
    Change
    Price
    $2.67
    N/A
    Market Cap
    $581.91M
    N/A
    Shares Outstanding
    217.94M
    N/A
    Employees
    53.00
    N/A
    logo
    Facebook Icon
    Twitter Icon
    Linkedin Icon
    Β© 2024 Topstocks.org